ICOSAVAX

Icosavax is a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases. Icosavax’s VLP platform technology is designed to enable multivalent, particle-based display of complex viral antigens, which it believes will induce broad, robust, and durable protection against the specific viruses targeted. Icosavax’s pipeline includes vaccine candida... tes targeting respiratory syncytial virus (RSV), human metapneumovirus (hMPV), and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Icosavax was formed in 2017 to advance the breakthrough VLP technology from the Institute for Protein Design at the University of Washington with the goal to discover, develop, and commercialize vaccines against infectious diseases.

#SimilarOrganizations #People #Financial #Website #More

ICOSAVAX

Social Links:

Facebook

Twitter

Industry:

Biotechnology Health Care Pharmaceutical

Founded:

2017-01-01

Address:

Seattle, Washington, United States

Country:

United States

Website Url:

http://www.icosavax.com

Total Employee:

11+

Status:

Active

Email Addresses:

[email protected]

Total Funding:

161 M USD

Technology used in webpage:

Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics LetsEncrypt Apple Mobile Web Clips Icon Google Tag Manager WordPress